Charles River Laboratories International Inc
CRL166.910USD
-2.730-1.61%
Close 08/01, 16:00（ET）Quotes delayed by 15 min
8.20BMarket Cap
LossP/E TTM
More Details of Charles River Laboratories International Inc Company
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Company Info
Ticker SymbolCRL
Company nameCharles River Laboratories International Inc
IPO dateJun 23, 2000
Founded at1994
CEOMr James C. Foster
Number of employees18600
Security typeOrdinary Share
Fiscal year-endJun 23
Address251 Ballardvale St
CityWILMINGTON
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code01887
Phone17812226000
Websitehttps://www.criver.com/
Ticker SymbolCRL
IPO dateJun 23, 2000
Founded at1994
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr James C. Foster
Mr James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
13.68K
-2.74%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
DSA
592.61M
60.21%
RMS
213.07M
21.65%
Manufacturing
178.49M
18.14%
By RegionUSD
Name
Revenue
Proportion
United States
536.96M
54.56%
Europe
263.25M
26.75%
Canada
125.35M
12.74%
Asia Pacific (Region)
41.94M
4.26%
Other
16.67M
1.69%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
DSA
592.61M
60.21%
RMS
213.07M
21.65%
Manufacturing
178.49M
18.14%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Allspring Global Investments, LLC
4.66%
Other
63.42%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.41%
Wellington Management Company, LLP
8.72%
BlackRock Institutional Trust Company, N.A.
5.92%
UBS Financial Services, Inc.
4.86%
Allspring Global Investments, LLC
4.66%
Other
63.42%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.51%
Investment Advisor/Hedge Fund
40.20%
Hedge Fund
7.75%
Research Firm
7.62%
Pension Fund
1.84%
Bank and Trust
1.48%
Sovereign Wealth Fund
1.10%
Individual Investor
1.05%
Insurance Company
0.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1392
55.35M
112.69%
-5.40M
2025Q1
1435
55.38M
112.72%
-5.93M
2024Q4
1423
54.85M
107.26%
-4.35M
2024Q3
1392
53.78M
105.14%
-5.12M
2024Q2
1399
54.00M
104.84%
-4.00M
2024Q1
1393
53.76M
104.37%
-4.04M
2023Q4
1424
53.56M
104.42%
-4.24M
2023Q3
1446
53.56M
104.42%
-3.98M
2023Q2
1427
52.88M
103.32%
-3.95M
2023Q1
1431
52.72M
103.01%
-2.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.09M
12.41%
-39.84K
-0.65%
Mar 31, 2025
Wellington Management Company, LLP
4.29M
8.72%
+208.59K
+5.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.91M
5.92%
-42.75K
-1.45%
Mar 31, 2025
UBS Financial Services, Inc.
2.39M
4.86%
+2.09M
+702.65%
Mar 31, 2025
Allspring Global Investments, LLC
1.77M
3.61%
-33.40K
-1.85%
Mar 31, 2025
Kayne Anderson Rudnick Investment Management, LLC
1.95M
3.97%
+144.73K
+8.02%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
3.87%
-278.81K
-12.78%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.26M
2.57%
+30.45K
+2.47%
Mar 31, 2025
Impactive Capital LP
1.21M
2.47%
+9.20K
+0.77%
Mar 31, 2025
Ariel Investments, LLC
1.10M
2.24%
+33.45K
+3.13%
Mar 31, 2025
View more
Related ETFs
Updated: 4 hours ago
Updated: 4 hours ago
Name
Proportion
First Trust NASDAQ Pharmaceuticals ETF
2.12%
Invesco S&P 500 Equal Weight Health Care ETF
1.66%
VanEck Biotech ETF
1.62%
ROBO Global Healthcare Technology & Innovation ETF
1.55%
Schwab Ariel Opportunities ETF
1.48%
Franklin Genomic Advancements ETF
1.38%
iShares Health Innovation Active ETF
1.27%
WisdomTree US Value Fund
0.96%
Principal Quality ETF
0.9%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.84%
View more
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.12%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.66%
VanEck Biotech ETF
Proportion1.62%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.55%
Schwab Ariel Opportunities ETF
Proportion1.48%
Franklin Genomic Advancements ETF
Proportion1.38%
iShares Health Innovation Active ETF
Proportion1.27%
WisdomTree US Value Fund
Proportion0.96%
Principal Quality ETF
Proportion0.9%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
Proportion0.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
